Welcome to our dedicated page for Evogene news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on Evogene stock.
Evogene Ltd. reports developments as a computational chemistry company focused on generative design of small molecules for pharmaceutical and agricultural applications. Its recurring updates center on ChemPass AI™, a proprietary generative AI platform used to explore chemical space and optimize small-molecule candidates across multiple parameters.
Company news also covers financial results, strategic refocusing around ChemPass AI™, collaborations in drug discovery and ag-chemical development, and subsidiary activity. Reported subsidiary themes include Casterra's castor seed varieties and castor farming systems for bio-based industries, AgPlenus work on novel herbicides and fungicides, Biomica microbiome-based therapeutics, and Nasdaq listing-compliance matters for EVGN ordinary shares.
Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced the appointment of Professor Itamar Grotto to its Board of Directors. Grotto, formerly of the Israeli Ministry of Health, brings extensive expertise in medical cannabis reform. His role aims to bolster Canonic's mission of developing medical cannabis products targeting specific medical indications. Grotto believes in the potential of Canonic to enhance patient care and expressed eagerness to contribute to the company's growth. CEO Arnon Heyman welcomed Grotto, emphasizing his valuable experience for advancing Canonic's strategic goals.
Evogene Ltd. (NASDAQ: EVGN) is set to release its financial results for the full year and fourth quarter of 2021 on March 10, 2022. Following the announcement, management will host a conference call at 09:00 AM Eastern time to discuss these results. The call can be accessed via phone or live webcast on the company's website. Evogene leverages advanced computational biology technologies to enhance life-science product development across various sectors including therapeutics and ag-chemicals.
Evogene Ltd. (NASDAQ-GM: EVGN) will present an overview at the Aegis Capital Corp. Virtual Conference from February 23 to 25, 2022. The presentation is set for February 25 at 9:00 AM EST. Interested participants can access the presentation upon request to Aegis or view the slide deck on Evogene's website. Evogene is a computational biology company aiming to innovate product development in life sciences, using its Computational Predictive Biology platform.
Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced the shipment of its first batch of cannabis varieties to Portugal after receiving export approval from the Israeli Ministry of Health and Ministry of Agriculture. This shipment is part of Canonic's preparations for a planned commercial launch in Europe in 2023, focusing on developing medical cannabis products using its Computational Predictive Biology platform. The shipped cannabis varieties will undergo lab testing and regulatory examination to comply with European regulations.
Evogene Ltd. (NASDAQ: EVGN) announced its participation in the Edison Group's Global Healthcare Open House Event from January 25-27, 2022. The event will take place virtually, and Evogene's presentation will be available on demand starting at 7 AM ET on January 27. Attendees can also register for 1x1 meetings with the company. Evogene utilizes its Computational Predictive Biology platform to advance product pipelines in various life-science sectors, including human health and agriculture.
Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced positive outcomes in pre-clinical studies focused on inflammation and pain relief involving specific cannabis varieties. Conducted by Hadassah Medical Center and Migal - Galilee Research Institute, these studies support Canonic's Precise product line aimed at medical cannabis. The company has filed a patent application for these cannabis varieties. The first products are projected for release in Israel in 2023, with plans to expand into Europe, as the medical cannabis market is expected to exceed €1 billion in Europe this year.
Biomica, a subsidiary of Evogene (NASDAQ: EVGN), received clearance from the Israeli Ministry of Health to proceed with a Phase I clinical trial for its drug candidate BMC-128. This trial will involve patients with Non-Small Cell Lung Cancer, Melanoma, or Renal Cell Carcinoma, evaluating BMC-128 in combination with Bristol Myers Squibb's Opdivo® (an anti-PD-1 therapy). The study aims to assess the safety and tolerability of this microbiome-based therapy at Rambam Health Care Campus.
Lavie Bio Ltd., a subsidiary of Evogene (NASDAQ: EVGN), has advanced its bio-fungicide program to the pre-commercialization stage, targeting fruit rot diseases. Following three years of vineyard trials in Europe and the U.S., promising results have been reported for LAV.311 and LAV.312. Lavie Bio prioritizes LAV.311 for regulatory submission to the U.S. EPA in 2022, aiming for a product launch in 2024. With an estimated $1 billion global market for fruit rot control, this advancement may present significant opportunities as concerns about chemical resistance rise.
Sapiens International Corporation (NASDAQ: SPNS) announced that Hiscox EU has successfully implemented Sapiens IDITSuite and Sapiens Intelligence in Germany. This deployment aims to enhance operational efficiency and productivity by up to 25% by 2025. Hiscox's multi-year IT strategy focuses on building a connected insurance ecosystem across Europe, starting with Germany and expanding to five additional countries. This transformation is expected to ensure sustainability and profitability amid increasing regulatory pressures.
Biomica, a subsidiary of Evogene (NASDAQ: EVGN), announced positive results from pre-clinical studies of its IBD drug candidate, BMC333. This candidate, combining four bacterial strains, has shown efficacy in reducing inflammation associated with inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn's disease, in animal models. The IBD treatment market was valued at USD 19.2 billion in 2020. Following encouraging results, Biomica plans to scale up development of BMC333 in 2022 and proceed with further pre-clinical studies.